12:00 AM
 | 
Sep 03, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Trastuzumab emtansine: Additional Phase III data

Additional data from the open-label, international Phase III EMILIA trial in 991 HER2-positive metastatic breast cancer patients showed that 3.6 mg/kg IV T-DM1 given every 3 weeks met the co-primary endpoint of improving OS vs. Tykerb lapatinib plus Xeloda capecitabine. Detailed data will be presented at an upcoming medical conference. In June, Roche and its Genentech Inc. unit reported that median OS had not yet been reached in the T-DM1 arm vs. 23.3 months for Tykerb plus Xeloda (HR=0.62, p=0.0005). At the time, Roche said the HR for OS did not cross the pre-specified stopping boundary (HR=0.617; p=0.0003) and that a...

Read the full 505 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >